Sandy Z Liu1, Dan P Zandberg2, Lisa M Schumaker3, John C Papadimitriou4, Kevin J Cullen2. 1. Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, United States. Electronic address: sliu1@umm.edu. 2. Department of Medicine, Division of Medical Oncology, University of Maryland School of Medicine, Baltimore, MD, United States; University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD, United States. 3. University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD, United States. 4. Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, United States.
Abstract
OBJECTIVES: Examine the effect of concordance between p16 overexpression and HR (high risk) HPV DNA status on overall survival in a large series of oropharyngeal squamous cell carcinoma (OPSCC) cases. MATERIALS AND METHODS: A total of 185 patients with primary OPSCC had genomic DNA tested by PCR for the HPV16 E6 and E7 oncogenes. 184 of 185 patients had p16 IHC performed. Linear array HPV genotyping was performed in all 21 HPV16/p16 discordant cases (HPV16+/p16- or HPV16-/p16+) as well as in 43 control cases. RESULTS: 73 of 185 patients were positive for HR HPV (39%). Six of 73 HPV infections were due to HR HPV types other than HPV16: types 31 (1), 33 (2), 51 (1), 58 (1), and 59 (1); all 6 cases were p16 positive. p16 IHC was concordant with HR HPV testing in 169 of 184 cases (92%), and had a sensitivity and specificity of 92% and 92%. HR HPV+/p16+ and discordant HR HPV/p16 patients had significantly improved overall survival compared to HR HPV-/p16- patients. CONCLUSION: p16 IHC is a reliable surrogate marker for HR HPV testing in OPSCC. Prognostically favorable HR HPV genotypes other than HPV16 are reflected in p16 positivity.
OBJECTIVES: Examine the effect of concordance between p16 overexpression and HR (high risk) HPV DNA status on overall survival in a large series of oropharyngeal squamous cell carcinoma (OPSCC) cases. MATERIALS AND METHODS: A total of 185 patients with primary OPSCC had genomic DNA tested by PCR for the HPV16 E6 and E7 oncogenes. 184 of 185 patients had p16 IHC performed. Linear array HPV genotyping was performed in all 21 HPV16/p16 discordant cases (HPV16+/p16- or HPV16-/p16+) as well as in 43 control cases. RESULTS: 73 of 185 patients were positive for HR HPV (39%). Six of 73 HPV infections were due to HR HPV types other than HPV16: types 31 (1), 33 (2), 51 (1), 58 (1), and 59 (1); all 6 cases were p16 positive. p16 IHC was concordant with HR HPV testing in 169 of 184 cases (92%), and had a sensitivity and specificity of 92% and 92%. HR HPV+/p16+ and discordant HR HPV/p16patients had significantly improved overall survival compared to HR HPV-/p16- patients. CONCLUSION:p16 IHC is a reliable surrogate marker for HR HPV testing in OPSCC. Prognostically favorable HR HPV genotypes other than HPV16 are reflected in p16 positivity.
Authors: Steven Habbous; Karen P Chu; Harold Lau; Melissa Schorr; Mathieos Belayneh; Michael N Ha; Scott Murray; Brian O'Sullivan; Shao Hui Huang; Stephanie Snow; Matthew Parliament; Desiree Hao; Winson Y Cheung; Wei Xu; Geoffrey Liu Journal: CMAJ Date: 2017-08-14 Impact factor: 8.262
Authors: Nicholas P Ambulos; Lisa M Schumaker; Trevor J Mathias; Ruth White; Jennifer Troyer; David Wells; Kevin J Cullen Journal: J Biomol Tech Date: 2016-03-07
Authors: Mushfiq H Shaikh; Aminul I Khan; Anwar Sadat; Ahmed H Chowdhury; Shahed A Jinnah; Vinod Gopalan; Alfred K Lam; Daniel T W Clarke; Nigel A J McMillan; Newell W Johnson Journal: BMC Cancer Date: 2017-11-25 Impact factor: 4.430
Authors: Paula Roberta Aguiar Pastrez; Vânia Sammartino Mariano; Allini Mafra da Costa; Estela Maria Silva; Cristovam Scapulatempo-Neto; Denise Peixoto Guimarães; Gilberto Fava; Said Abdala Zemi Neto; Emily Montosa Nunes; Laura Sichero; Luisa Lina Villa; Kari Juhani Syrjanen; Adhemar Longatto-Filho Journal: J Cancer Date: 2017-04-09 Impact factor: 4.207
Authors: Eric A Smith; Bhavna Kumar; Kakajan Komurov; Stephen M Smith; Nicole V Brown; Songzhu Zhao; Pawan Kumar; Theodoros N Teknos; Susanne I Wells Journal: Oncotarget Date: 2017-04-04
Authors: Nam P Nguyen; Ly M Nguyen; Sroka Thomas; Bevan Hong-Ly; Alexander Chi; Paul Vos; Ulf Karlsson; Vincent Vinh-Hung Journal: Medicine (Baltimore) Date: 2016-07 Impact factor: 1.889